Overview

'Fat Blaster' is a marketing name for a compounded lipotropic injection, a blend rather than a defined pharmaceutical. Typical components:

• L-carnitine -- shuttles long-chain fatty acids into mitochondria for beta-oxidation. A meta-analysis of 37 randomised trials found supplementation modestly reduced body weight (~1.2 kg), BMI and fat mass (Talenezhad et al., 2020), the strongest evidence among the ingredients.
• MIC (Methionine, Inositol, Choline) -- 'lipotropic' factors historically used to support hepatic fat metabolism. Choline and methionine participate in phospholipid and one-carbon metabolism and prevent hepatic fat accumulation in deficiency states, and inositol is involved in lipid signalling. However, robust clinical evidence that MIC injections cause weight loss in well-nourished people is lacking.
• B-vitamins (e.g. B12, B-complex) -- cofactors for energy metabolism; correct deficiency but do not independently drive fat loss.
• NADH -- a coenzyme central to cellular energy (oxidative phosphorylation), included for a purported energy/metabolic boost.

Rationale and honest appraisal: the blend is intended as an adjunct to a calorie-controlled diet and exercise, combining a fat-transport substrate (carnitine), hepatic lipotropics (MIC), metabolic cofactors (B-vitamins) and an energy coenzyme (NADH). In practice, only L-carnitine has meta-analytic weight-management data, and even that effect is small. Lipotropic 'fat-burner' injections are commonly offered by wellness and med-spa clinics but are not approved weight-loss therapies, and high-quality evidence for the combined product is absent. They are best viewed as supportive rather than primary treatments.

Mechanism of Action

L-carnitine's role in carnitine-palmitoyltransferase-mediated fatty-acid entry into mitochondria is well established biochemically, but its clinical weight effect is modest (Talenezhad et al. 2020). The lipotropic MIC factors act mainly on hepatic lipid handling and one-carbon/methylation pathways; their benefit is clearest in deficiency rather than as fat-loss agents in replete individuals. B-vitamins and NADH support the enzymatic and redox machinery of energy metabolism but do not by themselves induce a caloric deficit. The blend's overall effect on body weight in humans is not established by controlled trials.

Reconstitution Calculator

Safety Profile

Safety Profile: Fat Blaster

Common Side Effects

• Gastrointestinal distress: nausea, bloating, diarrhea, and abdominal cramping (common with thermogenic and fiber-based blends)
• Jitteriness, nervousness, and anxiety due to stimulant ingredients (caffeine, green tea extract, synephrine)
• Insomnia and disrupted sleep patterns, especially with afternoon or evening dosing
• Increased heart rate (tachycardia) and palpitations
• Headache and dizziness
• Excessive sweating and flushing
• Dry mouth and increased thirst
• Appetite suppression (intended effect but may lead to inadequate nutrition)

Serious Adverse Effects

• Cardiovascular events: Hypertension, arrhythmias, and rare cases of myocardial infarction or stroke associated with high-stimulant thermogenic blends
• Hepatotoxicity: Green tea extract (EGCG) at high doses linked to liver injury; rare cases of acute liver failure reported with weight-loss supplements
• Rhabdomyolysis: Rare but reported with stimulant-heavy formulations combined with intense exercise
• Serotonin syndrome: If formulation contains 5-HTP or tryptophan combined with serotonergic medications
• Adrenal stress: Chronic use of high-dose stimulant blends may contribute to HPA axis dysregulation
• Electrolyte imbalances: Products with diuretic or laxative components may cause dangerous hypokalemia or hyponatremia
• Note: "Fat Blaster" formulations vary by brand; ingredient profiles differ significantly and safety profiles depend on specific composition

Contraindications

• Cardiovascular disease (hypertension, arrhythmias, coronary artery disease, heart failure)
• Anxiety disorders or panic disorder
• Hyperthyroidism or thyroid disorders
• Seizure disorders
• Hepatic impairment or history of liver disease
• Pregnancy and breastfeeding
• Children and adolescents under 18 years
• Current use of MAO inhibitors
• Caffeine sensitivity or intolerance
• Eating disorders (anorexia nervosa, bulimia)

Drug Interactions

• MAO inhibitors: Dangerous hypertensive crisis with sympathomimetic ingredients (synephrine, tyramine-containing compounds)
• Stimulant medications (amphetamines, methylphenidate): Additive cardiovascular stimulation; significant arrhythmia risk
• SSRIs/SNRIs: Risk of serotonin syndrome if supplement contains 5-HTP; additive jitteriness and anxiety
• Antihypertensives: Stimulant ingredients may counteract blood pressure-lowering effects
• Thyroid medications (levothyroxine): Some ingredients may alter thyroid hormone levels or absorption
• Anticoagulants (warfarin): Multiple herbal ingredients may alter INR; close monitoring required
• Diabetes medications: Appetite suppression and metabolic effects may cause unpredictable blood glucose changes
• Caffeine-containing beverages/medications: Additive caffeine load may exceed 400 mg/day safe threshold

Population-Specific Considerations

• Healthy adults: Even in healthy populations, limit use to recommended durations (typically 8-12 weeks maximum); cycle off for equal periods
• Elderly: Avoid stimulant-based formulations; increased cardiovascular and fall risk
• Pediatric/Adolescents: Strictly contraindicated; may interfere with growth and development
• Pregnant/Lactating: Absolutely contraindicated; stimulants and thermogenics pose fetal and neonatal risk
• Cardiovascular patients: Avoid entirely; stimulant burden is dangerous
• Mental health patients: Stimulant ingredients may worsen anxiety, insomnia, and mood disorders
• Athletes: Check for banned substances (some formulations contain prohibited stimulants); verify with third-party testing
• Critical note: Supplement quality varies enormously; choose products with third-party certification (NSF, USP, Informed Sport); proprietary blends obscure actual ingredient doses

Pharmacokinetic Profile